Startup profile · funding coverage
Chai Discovery funding, valuation and investors
AI molecular-design company licensing research models and tools to pharmaceutical teams.
Verified company research · funding, investors and latest developments
Keep track of Chai Discovery
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$400M · July 14, 2026
Latest known valuation
$3.8B valuation (company announcement; valuation basis not specified)
Series C · July 14, 2026
Total disclosed equity funding
$400M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · San Francisco, California, United States
Investors in latest funding
Lead: Index Ventures
Other: Kleiner Perkins , Sequoia Capital , Dimension
Overview
Chai Discovery develops foundation models and computer-aided design tools for antibodies and molecules. The company announced a $400 million Series C on July 14, 2026. Its research and news page lists collaborations with Pfizer, Lilly, Novartis, Bristol Myers Squibb, GSK, Roche and other biopharma partners.
These collaborations differ in scope and undisclosed commercial terms, so partnership counts must not be equated with recognized revenue. Chai disclosed a $3.8B valuation with its Series C; its public post does not specify a pre- or post-money basis. Source: https://www.chaidiscovery.com/news/series-c
Why Chai Discovery is interesting
A July 2026 $400M Series C coincided with a growing list of named pharma collaborations; commercial renewals and demonstrated experimental outcomes matter more than announced partnership counts.
Product & use cases
Molecular structure prediction, antibody design models and drug research workflows for enterprise pharmaceutical scientists.
Funding history (newest first)
Series C
2026-07-14 $400M Valuation: $3.8B valuation (company announcement; valuation basis not specified)- Index Ventures (lead)
- Kleiner Perkins (participant)
- Sequoia Capital (participant)
- Dimension (participant)
Source: Read source · chaidiscovery.com
Competitive landscape
Edge: Named pharmaceutical customers and iterative model-development and deployment focus.
Chai sells technology rather than presenting a mature internally commercialized drug franchise. A pharmaceutical company's use of a model does not mean that a therapeutic candidate has passed clinical testing.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Chai Discovery
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.